JW Pharmaceutical said Sunday that it gained the South Korean drug regulator's approval to begin domestic sales of the hemophilia treatment Hemlibra, developed by Roche's Chugai unit, reported The Korea Herald.

Specifically, the agency approved the antibody for the treatment of patients with hemophilia A, with or without factor VIII inhibitors.

JW Pharmaceuticals, which obtained an exclusive license to sell Hemlibra on the Korean market in 2017, will begin sales of Hemlibra in Korea after negotiating pricing with the nation's Health Insurance Review and Assessment Service.

Global pharmaceutical market analysts predict that Hemlibra will bring in 5 trillion won in annual sales in the global hemophilia market.

Register as Visitor to CPhI China 2019!